VOLUNTARY ANNOUNCEMENT - RECOMBINANT FULLY HUMAN ANTI-Beta Klotho MONOCLONAL ANTIBODY DRUG (JMT202) OBTAINS CLINICAL TRIAL APPROVAL

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement. (Incorpor ated in H ong Kong with limi ted liabi lity) (Stock co de: 1093) VOLUNTARY ANNOUNCEMENT RECOMBINANT FULLY HUMAN ANTI-βKlotho MONOCLONAL ANTIBODY DRUG (JMT202) OBTAINS CLINICAL TRIAL APPROVAL The board of directors (the “Board”) of CSPC Pharmaceutical Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that the recombinant fully human anti-βKlotho monoclonal antibody drug (JMT202) (the “Product”) developed by the Group, has obtained approval from the National Medical Products Administration of the People’s Republic of China to conduct clinical trials in China. The Product is an FGFR1c/βKlotho receptor agonist, which regulates glycolipid metabolism by binding to βKlotho protein and specifically activating the FGFR1c/βKlotho receptor complex, thereby mimicking the action of its natural ligand, FGF21 protein. The Product is potentially useful for the treatment of metabolism-related diseases such as dyslipidemia, non-alcoholic steatohepatitis (NASH), type 2 diabetes, and obesity. Furthermore, it has the potential to be used in combination with other targeted drugs (such as GLP-1) that regulate glycolipid metabolism. The indication for this clinical trial approval is to lower triglyceride (TG) levels in patients with hypertriglyceridaemia. Preclinical studies demonstrated that the Product has a good safety profile, long dosing intervals, significant reduction in triglycerides levels, and hypolipidemic effect on the liver, thus providing a promising clinical development value. By order of the Board CSPC Pharmaceutical Group Limited CAI Dongchen Chairman Hong Kong, 17 May 2024 - 1 - As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. WANG Qingxi, Mr. CHAK Kin Man and Dr. JIANG Hao as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive directors. - 2 -

The release as fetched from its publisher. irasia.com ↗